Low Insulin-like Growth Factor-II Levels Predict Weight Gain in Normal Weight Subjects with Type 2 Diabetes - 18/08/11
, Lars Kärvestedt, MD b, c, Simon G. Anderson, PhD a, Julie McLaughlin, BSc a, Anne Knowles, BSc d, Louise Wong, BSc a, Valdemar Grill, MD c, J. Kennedy Cruickshank, MD d, Anne White, PhD e, J. Martin Gibson, MD a, Kerstin Brismar, MD c
Requests for reprints should be addressed to Adrian H. Heald, DM, Department of Diabetes and Endocrinology, University of Manchester, Salford Royal Hospitals University Trust, Hope Hospital, Stott Lane, Salford, Greater Manchester, M68HD, UKAbstract |
Purpose |
Insulin-like growth factor (IGF)-I and IGF-II are important in the regulation of metabolism and growth. We previously reported in normoglycemic individuals of normal weight that low circulating IGF-II predicts future weight gain. We subsequently investigated whether such relationships persisted in circumstances of type 2 diabetes.
Methods |
In 224 subjects with type 2 diabetes we assessed the association between baseline IGF-II levels and risk of weight gain (>2.0 kg) at the 5-year follow-up.
Results |
At follow-up, 90 participants (40.2%) gained more than 2.0 kg in body weight. For subjects (body mass index <26) at baseline, mean IGF-II levels were significantly lower in those who gained more than 2 kg in weight than in subjects of stable weight, 454 ng/mL (95% confidence interval 349-559) versus 620 ng/mL (534-705) (F=7.4, P=.01). For this subgroup low circulating IGF-II at baseline strongly correlated with weight gain (Spearman rho=−0.52, P <.001). With increasing weight, the relationship no longer prevailed. Logistic regression showed that for body mass index less than 26, individuals at baseline for each 100 ng/mL increase in baseline IGF-II there was a 47% decreased risk of gaining 2.0 kg or more in weight. Adjustment for treatment group did not materially alter this relationship. There was no difference in baseline IGF-II by treatment group. There was no difference between the group with weight gain and the group with stable weight in those who additionally received insulin or sulfonylurea treatment in the 5 years between the baseline visit and the follow-up.
Conclusions |
In subjects of normal weight with type 2 diabetes, baseline IGF-II concentration is inversely related to future weight gain, independent of treatment effect, strengthening the putative role for IGF-II in regulating fat mass. We propose that IGF-II measurement has potential utility in this group for targeting such individuals for early intervention.
Le texte complet de cet article est disponible en PDF.Keywords : IGF-II, Type 2 diabetes, Weight gain
Plan
| The NHS North-West Research and Development Directorate funded the work of AH in this project, and Salford Royal Hospitals NHS Trust funded technical support. Support was also given by the Swedish Diabetes Foundation and the S. Persson Family Foundation. |
Vol 119 - N° 2
P. 167.e9-167.e15 - février 2006 Retour au numéro
Article précédent
- Progestins Affect Mechanism of Estrogen-induced C-reactive Protein Stimulation
- David B. Reuben, Shana L. Palla, Peifeng Hu, Beth A. Reboussin, Carolyn Crandall, David M. Herrington, Elizabeth Barrett-Connor, Gail A. Greendale
- Disparities in the Use of Primary Prevention and Defibrillator Therapy Among Blacks and Women
- Andre J. Gauri, Andrew Davis, Thomas Hong, Martin C. Burke, Bradley P. Knight
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?